137 related articles for article (PubMed ID: 18502845)
1. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.
Haroche J; Amoura Z; Charlotte F; Salvatierra J; Wechsler B; Graux C; Brousse N; Piette JC
Blood; 2008 Jun; 111(11):5413-5. PubMed ID: 18502845
[No Abstract] [Full Text] [Related]
2. Response of histiocytoses to imatinib mesylate: fire to ashes.
Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
[No Abstract] [Full Text] [Related]
3. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
5. Erdheim-Chester disease harboring the BRAF V600E mutation.
Blombery P; Wong SQ; Lade S; Prince HM
J Clin Oncol; 2012 Nov; 30(32):e331-2. PubMed ID: 23008323
[No Abstract] [Full Text] [Related]
6. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
[TBL] [Abstract][Full Text] [Related]
7. Molecular framework for response to imatinib mesylate in systemic sclerosis.
Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
[TBL] [Abstract][Full Text] [Related]
8. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
9. [Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy].
Mauri M; García M; Reynaga E; Ramila E
Med Clin (Barc); 2007 Jun; 129(4):159. PubMed ID: 17663975
[No Abstract] [Full Text] [Related]
10. The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases.
Sleijfer S; Wagner AJ
J Clin Oncol; 2012 Mar; 30(9):896-8. PubMed ID: 22331936
[No Abstract] [Full Text] [Related]
11. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.
Garcia JL; Font de Mora J; Hernandez JM; Queizan JA; Gutierrez NC; Hernandez JM; San Miguel JF
Blood; 2003 Oct; 102(7):2699-700. PubMed ID: 14504072
[No Abstract] [Full Text] [Related]
12. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract][Full Text] [Related]
13. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb A; Constans J; Mahon FX
Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
[No Abstract] [Full Text] [Related]
14. The role of imatinib in the treatment of pulmonary hypertension.
Mucke H
Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?
Erre GL; Pardini S; Cuccuru L; Taras L; Passiu G
Joint Bone Spine; 2015 Jan; 82(1):72-3. PubMed ID: 25059880
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate induces clinical remission in rheumatoid arthritis.
Pereira I; Fialho S; Castro G; Zimmermann A
Joint Bone Spine; 2010 Jul; 77(4):372-3. PubMed ID: 20478730
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
18. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
19. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Chhina MK; Nargues W; Grant GM; Nathan SD
Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
[TBL] [Abstract][Full Text] [Related]
20. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
[Next] [New Search]
